colorectal cancer
Conditions
Interventions
1:Tegafur combined with Thalidomide
2:Tegafur
Sponsors
First Affilliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) histologicallyconfirmed colorectal cancer (adenocarcinoma); (2) aged 18 to 75 years; (3) at least one measurable metastatic lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST); (4) failure of at least two prior chemotherapies, one including oxaliplatin 5-Fu and irinotecan, for mCRC (5) Eastern CooperativeOncology Group (ECOG) performance status (PS) of 0–2; (6) estimate survival more than 3 months; (7) negative for pregnany; (8) ascites(slight) but do not need treatment; (9) adequate renal, liver,hematologic, and coagulation function; (10) known MSI-H, but could not offord immunotherapy nor could not tolerant immunotherapy.
Exclusion criteria
Exclusion criteria: (1) contraception was not used for patients in reproductive stage; (2) patients with intestinal obstruction; (3) history or evidence of thombus; (4) allergic to S-1 or thalidomide; (5) prior S-1 therapy; (6) patients with active infection; (7) with other conditions that is not appropriate to chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease control rate; | — |
Countries
China
Contacts
Public ContactXuyuan Dong
The First Affilliated Hospital of Xi'an Jiaotong University
Outcome results
None listed